| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $1.3M | 0.01% | 2.38M | +279% | Q2 2026 |
| Renaissance Technologies | $73.6K | 0.00% | 133.90K | +4.5% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ENLV trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ENLV.
TimeframesDown on all 2 timeframes: no timeframe is holding up.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.6 | 13.9 | -19.1 | -11.9 | -1.2 | -32.1 | -74.7 | -38.8 | -60.7 | -66.2 | −98.4% | ||
| 2025 | -6.0 | 9.1 | -19.1 | 5.1 | -8.2 | 19.7 | 33.0 | -29.5 | -1.0 | 1.0 | -7.6 | -27.5 | −39.9% |
| 2024 | 3.7 | 10.9 | 22.1 | -55.9 | -18.6 | 4.4 | -5.6 | -3.0 | 29.2 | -19.6 | -15.6 | 2.6 | −56.7% |
| 2023 | 11.2 | -8.7 | -9.0 | -22.0 | -7.7 | 0.3 | -2.6 | -6.6 | -33.9 | -15.8 | 38.3 | 46.7 | −31.4% |
| 2022 | -14.6 | 0.2 | 4.5 | 1.8 | -12.0 | -9.8 | -6.0 | 23.5 | -19.0 | 0.9 | 6.9 | -14.1 | −37.0% |
| 2021 | 41.8 | 27.9 | -27.5 | 3.2 | -18.1 | -5.0 | -14.6 | 82.4 | -28.7 | -16.6 | -15.0 | -10.7 | −25.9% |
| 2020 | -4.9 | 12.2 | -47.7 | 17.3 | -5.5 | -2.5 | 7.9 | -4.9 | 14.5 | 85.9 | -23.4 | -0.4 | +0.5% |
| 2019 | 41.5 | 15.1 | 23.0 | -15.4 | 10.4 | 85.7 | 4.8 | 23.8 | -4.2 | -75.0 | 30.1 | -3.3 | +35.6% |
| 2018 | 25.1 | -5.9 | -26.4 | 11.1 | -0.5 | -25.2 | -29.4 | 9.3 | 6.8 | -0.7 | -5.2 | -39.1 | −66.2% |
| 2017 | 35.6 | -26.2 | -26.9 | -26.3 | -16.1 | 42.6 | 1.2 | -14.4 | -25.3 | 15.9 | -11.6 | 3.0 | −56.0% |
| 2016 | -5.4 | -24.0 | -10.4 | -10.0 | -10.7 | -20.0 | 7.5 | -5.8 | 6.8 | -12.1 | -9.2 | -24.6 | −73.1% |
| 2015 | 27.5 | -16.8 | -11.5 | -5.0 | 0.9 | 19.8 | -6.0 | -9.9 | -12.8 | -2.8 | 4.0 | -24.9 | −39.4% |
| 2014 | 10.0 | -21.3 | -24.3 | 25.5 | -7.4 | −23.9% |
Buy / hold / sell counts
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.